問卷

TPIDB > Search Result

Search Result

篩選

List

25Cases

2021-11-01 - 2029-03-18

Phase III

Active
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis
  • Condition/Disease

    Generalized Myasthenia Gravis

  • Test Drug

    注射液 注射液

Participate Sites
5Sites

Recruiting5Sites

2022-04-01 - 2025-09-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2021-12-01 - 2026-09-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2023-12-15 - 2028-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-01-01 - 2027-12-31

Phase III

Active
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis
  • Condition/Disease

    Generalized Myasthenia Gravis

  • Test Drug

    injection

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2020-01-01 - 2025-12-31

Phase III

Completed
A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • Condition/Disease

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • Test Drug

    ENSPRYNG 120mg for SC Injection

Participate Sites
4Sites

Recruiting4Sites

2023-12-15 - 2028-06-30

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
  • Condition/Disease

    Transthyretin amyloid cardiomyopathy

  • Test Drug

    ALXN2220

Participate Sites
5Sites

Recruiting5Sites

2024-07-01 - 2026-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-11-30 - 2024-03-11

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 2 3